SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of...
SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of...
SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family...
SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to...
QuidelOrtho's secondary offering of 8.26 million shares is priced at $38.58, removing an investor overhang, according to William Blair's analysis.
Quidel (NASDAQ:QDEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:10 PM. Here's what investors need to know about the announcement. Earnings Quidel beat estimated earnings by 17.9%, reporting an EPS of $11.66 versus an estimate of $9.89.
